m+Medelevator.RU
← Поиск публикаций
Scientific reports · 2026

A dual-drug chitosan-hyaluronic acid bandage contact lens accelerates corneal re-epithelialization in a rabbit mechanical debridement model.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Aghamirsalim Mohamadreza, Sadeghi Erfan, Jabbarvand Mahmood, Famildardashti Farshad, Famildardashti Farzad, Sahraian Alireza

Аннотация

Rapid corneal re-epithelialization is crucial to prevent infection and scarring, yet the efficacy of conventional topical therapies is hindered by their limited ocular bioavailability. To address this, we developed a daily replaceable chitosan-hyaluronic acid (CS-HA) bandage contact lens co-loaded with levofloxacin and betamethasone using a soaking-based drug-loading approach. In a rabbit 8-mm mechanical corneal debridement model (n = 15/group), the dual-drug CS-HA lens was compared with a chitosan-only drug-loaded lens, a commercial silicone-hydrogel bandage lens plus drops, and drops alone. The CS-HA lens maintained adequate optical transparency, water content, and oxygen permeability suitable for short-term wear. In vitro assays showed that the dual-drug CS-HA lens retained antibacterial inhibitory activity in agar diffusion tests and reduced TNF-α secretion in an LPS-stimulated THP-1 assay. Re-epithelialization was significantly faster with the CS-HA lens, achieving complete closure at a median of 3 days versus 5, 6, and 8 days in the respective control groups. Day-10 histology showed a well-stratified epithelium with no evidence of stromal inflammatory infiltration in the CS-HA group, whereas controls exhibited greater stromal disorganization. This biocompatible dual-drug platform may accelerate ocular surface restoration and reduce reliance on frequent topical dosing in settings such as post-refractive surgery care and persistent epithelial defects.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты